188 related articles for article (PubMed ID: 10889124)
1. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Cannon CP; McCabe CH; Wilcox RG; Langer A; Caspi A; Berink P; Lopez-Sendon J; Toman J; Charlesworth A; Anders RJ; Alexander JC; Skene A; Braunwald E
Circulation; 2000 Jul; 102(2):149-56. PubMed ID: 10889124
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
O'Connor FF; Shields DC; Fitzgerald A; Cannon CP; Braunwald E; Fitzgerald DJ
Blood; 2001 Dec; 98(12):3256-60. PubMed ID: 11719362
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Scirica BM; Cannon CP; Cooper R; Aster RH; Brassard J; McCabe CH; Charlesworth A; Skene AM; Braunwald E
J Thromb Thrombolysis; 2006 Oct; 22(2):95-102. PubMed ID: 17008974
[TBL] [Abstract][Full Text] [Related]
4. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial.
Atar S; Cannon CP; Murphy SA; Rosanio S; Uretsky BF; Birnbaum Y
Am Heart J; 2006 May; 151(5):976.e1-6. PubMed ID: 16644315
[TBL] [Abstract][Full Text] [Related]
5. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Cotter G; Cannon CP; McCabe CH; Michowitz Y; Kaluski E; Charlesworth A; Milo O; Bentley J; Blatt A; Krakover R; Zimlichman R; Reisin L; Marmor A; Lewis B; Vered Z; Caspi A; Braunwald E;
Am Heart J; 2003 Apr; 145(4):622-7. PubMed ID: 12679757
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
Cannon CP; McCabe CH; Borzak S; Henry TD; Tischler MD; Mueller HS; Feldman R; Palmeri ST; Ault K; Hamilton SA; Rothman JM; Novotny WF; Braunwald E
Circulation; 1998 Feb; 97(4):340-9. PubMed ID: 9468207
[TBL] [Abstract][Full Text] [Related]
7. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes.
Serrano CV; Nicolau JC; Venturinelli M; Baracioli LM; Anders RJ; Cannon CP; Ramires JA
Cardiovasc Drugs Ther; 2003 Mar; 17(2):129-32. PubMed ID: 12975594
[TBL] [Abstract][Full Text] [Related]
8. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Chew DP; Bhatt DL; Sapp S; Topol EJ
Circulation; 2001 Jan; 103(2):201-6. PubMed ID: 11208677
[TBL] [Abstract][Full Text] [Related]
9. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
Newby LK
Am Heart J; 1999 Aug; 138(2 Pt 1):210-8. PubMed ID: 10426831
[TBL] [Abstract][Full Text] [Related]
10. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
[TBL] [Abstract][Full Text] [Related]
11. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction.
Holmes MB; Sobel BE; Cannon CP; Schneider DJ
Am J Cardiol; 2000 Feb; 85(4):491-3, A10. PubMed ID: 10728957
[TBL] [Abstract][Full Text] [Related]
12. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes.
Cox D; Smith R; Quinn M; Theroux P; Crean P; Fitzgerald DJ
J Am Coll Cardiol; 2000 Nov; 36(5):1514-9. PubMed ID: 11079651
[TBL] [Abstract][Full Text] [Related]
13. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
[TBL] [Abstract][Full Text] [Related]
15. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM;
Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
N Engl J Med; 1998 Aug; 339(7):436-43. PubMed ID: 9705684
[TBL] [Abstract][Full Text] [Related]
18. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD;
JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194
[TBL] [Abstract][Full Text] [Related]
19. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.
Circulation; 1998 Jun; 97(24):2386-95. PubMed ID: 9641689
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
Topol EJ; Easton D; Harrington RA; Amarenco P; Califf RM; Graffagnino C; Davis S; Diener HC; Ferguson J; Fitzgerald D; Granett J; Shuaib A; Koudstaal PJ; Theroux P; Van de Werf F; Sigmon K; Pieper K; Vallee M; Willerson JT;
Circulation; 2003 Jul; 108(4):399-406. PubMed ID: 12874182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
